Dynamics of Behavioral Disorders in Transgenic Mice with Modeled Alzheimer’s Disease

Age-related development of behavioral disorders in transgenic mice with modeled Alzheimer’s disease carrying V6S3-Tg(APP695)85Dbo Tg(PSENI)85Dbo) genotype was assessed at the age of 7.5, 10 and 20 months in the following tests: open-field, plus maze, T-maze, conditioned passive avoidance response, r...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Bulletin of experimental biology and medicine 2015-03, Vol.158 (5), p.621-623
Hauptverfasser:	Semina, I. I., Baichurina, A. Z., Makarova, E. A., Leushina, A. V., Kazakevich, Zh. V., Gabdrakhmanova, M. R., Mukhamed’yarov, M. A., Zefirov, A. L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Alzheimer Disease - drug therapy Alzheimer Disease - pathology Alzheimer Disease - physiopathology Alzheimer's disease Amyloid beta-Protein Precursor - genetics Animals Anti-Alzheimer's disease agents Anxiety - drug therapy Anxiety - pathology Anxiety - physiopathology Avoidance Learning - drug effects Behavior, Animal - drug effects Biomedical and Life Sciences Biomedicine Cell Biology Depression (Mood disorder) Disease Models, Animal Genetic engineering Internal Medicine Laboratory Medicine Maze Learning - drug effects Memory Disorders - drug therapy Memory Disorders - pathology Memory Disorders - physiopathology Mice Mice, Transgenic Neuroprotective Agents - therapeutic use Pathology Tremor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Age-related development of behavioral disorders in transgenic mice with modeled Alzheimer’s disease carrying V6S3-Tg(APP695)85Dbo Tg(PSENI)85Dbo) genotype was assessed at the age of 7.5, 10 and 20 months in the following tests: open-field, plus maze, T-maze, conditioned passive avoidance response, rotarod, conflict situation with water deprivation, behavioral despair, and arecoline tremor. The main behavioral disorder in transgenic mice at all observation terms was memory impairment in conditioning with positive (but not negative) reinforcement. At the age of 7.5 and 10 months, transgenic mice also showed signs of nonspecific excitement and anxiety, depression-like state, and symptoms of cholinergic deficit. Our results suggest that appropriate age for behavioral tests in studies of effects of potential anti-Alzheimer drugs in transgenic V6S3-Tg(APP695)85Dbo Tg(PSENI)85Dbo) mice is 7.5-10 months.
ISSN:	0007-4888 1573-8221
DOI:	10.1007/s10517-015-2821-0